drugset / Trial / NCT01825785
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
RandomizedSequentialDouble-blindTreatment
Summary
The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone mass.
Timeline
- Start
- 2007-11-14
- Primary completion
- 2008-12-02
- Completion
- 2008-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romosozumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | Romosozumab | Monoclonal antibody | 2 mg/kg | Subcutaneous |
| Subject | Romosozumab | Monoclonal antibody | 3 mg/kg | Subcutaneous |
Indications
No indication recorded.